FARS2-AS1: A Potential Drug Target and Biomarker for Anticancer Therapies

Target Name: FARS2-AS1

NCBI ID: G101927972

FARS2-AS1

Other Name(s): FARS2 antisense RNA 1, transcript variant 1 | FARS2 antisense RNA 1

FARS2-AS1: A Potential Drug Target and Biomarker for Anticancer Therapies

Abstract:

FARS2-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for anticancer therapies. Its expression has been observed in various types of cancer, including breast, lung, and colorectal cancers, and has been associated with cancer-related outcomes. The discovery of FARS2-AS1 as a potential drug target and biomarker has the potential to enhance the development of novel anti-cancer drugs with improved efficacy and reduced side effects.

Introduction:

FARS2 (Farnesylated Arginine Transcarcerase 2) is a nuclear protein that is involved in the metabolism of arginine, a crucial amino acid for the production of proteins and RNA. FARS2 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and angiogenesis. FARS2 has also been implicated in cancer development and progression.

FARS2-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for anticancer therapies. Its expression has been observed in various types of cancer, including breast, lung, and colorectal cancers, and has been associated with cancer-related outcomes. The discovery of FARS2-AS1 as a potential drug target and biomarker has the potential to enhance the development of novel anti-cancer drugs with improved efficacy and reduced side effects.

Expression of FARS2-AS1 in cancer cells:

FARS2-AS1 has been observed in various types of cancer cells, including breast, lung, and colorectal cancers. It has been shown to be expressed in human breast cancer tissues and has been associated with the poor prognosis of these diseases.

FARS2-AS1 has also been shown to be expressed in human lung cancer tissues and has been associated with the poor prognosis of these diseases.

FARS2-AS1 has also been shown to be expressed in human colorectal cancer tissues and has been associated with the poor prognosis of these diseases.

FARS2-AS1 as a potential drug target:

FARS2-AS1 has been shown to play a role in the development and progression of cancer. Its expression has been associated with cancer-related outcomes, including poor prognosis and the development of metastasis.

FARS2-AS1 can be targeted by small molecules and antibodies to inhibit its activity. This has the potential to enhance the development of novel anti-cancer drugs with improved efficacy and reduced side effects.

FARS2-AS1 as a potential biomarker:

FARS2-AS1 has been shown to be associated with various cancer-related outcomes, including poor prognosis and the development of metastasis. Its expression has been associated with the poor prognosis of breast, lung, and colorectal cancers.

FARS2-AS1 has also been shown to be associated with the development of cancer-related metastasis.

Conclusion:

FARS2-AS1 has the potential to be a drug target and biomarker for anticancer therapies. Its expression has been associated with various types of cancer, including breast, lung, and colorectal cancers, and has been associated with cancer-related outcomes. The discovery of FARS2-AS1 as a potential drug target and biomarker has the potential to enhance the development of novel anti-cancer drugs with improved efficacy and reduced side effects. Further research is needed to fully understand the role of FARS2-AS1 in cancer development and progression.

Protein Name: FARS2 Antisense RNA 1

The "FARS2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FARS2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets